Argentarii LLC Purchases 9,280 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Argentarii LLC grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 268.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 12,732 shares of the medical research company's stock after buying an additional 9,280 shares during the period. Argentarii LLC's holdings in Edwards Lifesciences were worth $923,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in EW. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter worth about $26,000. Vega Investment Solutions acquired a new position in Edwards Lifesciences in the fourth quarter worth about $27,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth about $29,000. Global X Japan Co. Ltd. raised its position in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC raised its position in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Piper Sandler increased their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 13th. Citigroup reissued a "buy" rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and an average target price of $80.20.

Insider Activity at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the transaction, the vice president directly owned 33,496 shares of the company's stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,648 shares of company stock valued at $2,998,866. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 0.2%

EW stock traded down $0.15 during midday trading on Monday, reaching $76.64. The company's stock had a trading volume of 2,503,550 shares, compared to its average volume of 5,242,909. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The stock has a market cap of $44.96 billion, a PE ratio of 10.95, a price-to-earnings-growth ratio of 3.86 and a beta of 1.11. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The business's 50-day simple moving average is $76.12 and its 200-day simple moving average is $73.27.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $0.66 earnings per share. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.